Entheon Biomedical Announces Non-Brokered Private Placement Financing Post published:April 5, 2022 Post category:Press Release
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical Research Platform Post published:March 29, 2022 Post category:Press Release
Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT Post published:March 15, 2022 Post category:Press Release
Entheon Biomedical Announces EBIQ-101 First-Patient Dose Post published:February 24, 2022 Post category:Press Release
Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study Post published:February 16, 2022 Post category:Press Release
Entheon Biomedical Announces the Approval of DMT Clinical Trial Post published:February 3, 2022 Post category:Press Release
Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today Post published:January 18, 2022 Post category:Press Release
Entheon Biomedical Corp. Files Preliminary Shelf Prospectus Post published:January 18, 2022 Post category:Press Release
Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory Submission to Ethics Committee Post published:January 6, 2022 Post category:Press Release
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel Post published:December 21, 2021 Post category:Press Release